Company Overview of NuPathe, Inc.
NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transport...
7 Great Valley Parkway
Malvern, PA 19355
Founded in 2005
Key Executives for NuPathe, Inc.
Chief Executive Officer and Director
Chief Commercial Officer and Senior Vice President
Chief Scientific Officer and Vice President
Compensation as of Fiscal Year 2014.
NuPathe, Inc. Key Developments
NuPathe, Inc.(NasdaqGM:PATH) dropped from NASDAQ Composite Index
Feb 23 14
NuPathe, Inc. will be removed from the NASDAQ Composite Index.
NuPathe, Inc. Announces Amendments to its Certificate of Incorporation
Feb 21 14
NuPathe, Inc. announced that pursuant to the terms of the Merger Agreement, the company's certificate of incorporation was amended and restated in its entirety, effective as of the effective time.
NuPathe, Inc. Presents at The Goldman Sachs Technology and Internet Conference 2014, Feb-11-2014 09:00 AM
Feb 10 14
NuPathe, Inc. Presents at The Goldman Sachs Technology and Internet Conference 2014, Feb-11-2014 09:00 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 8, 2014
December 16, 2013
Most Searched Private Companies
Sponsored Financial Commentaries